Q4 2025 earnings call: 15% revenue growth, $3.9M sales, CapsoCam Colon Gen 2/AI 510(k) timing, trials & funding—read now.
Phase 2 TBCRC049 trial results show tucatinib triplet therapy improves survival in HER2+ breast cancer patients with ...
Clients and government officials mingled with SMEs bringing fresh ideas for building better at this year’s two-day conference ...
Tigris publication confirms positive results for primary and key secondary endpoints with 95.3% and 99.4% probability of benefit for PMX at 28-day and 90-day mortality After adjusting for baseline ...
The Federal Network Agency has initiated 77 proceedings against network operators. This is likely just the beginning, as the rollout is still lagging.
The Kolmogorov-Arnold Network (abbr. KAN) is a novel neural network architecture inspired by the Kolmogorov-Arnold ...
CESTAT ruled that communication from the supplier and supporting photographs clarified the actual quantity of imported memory modules, negating the charge of ...
Keysight Technologies, Inc. (NYSE: KEYS) today introduced the Functional Interconnect Test Solutions (FITS) portfolio and ...
Active Surfaces, a startup based on solar-energy technologies rooted in MIT research, is well on its way to developing what ...
Joining me on today’s call are Sean Nolan, Taysha Gene Therapies, Inc.'s Chief Executive Officer; Sukumar Nagendran, ...
The Artemis II mission patch is seen on the right shoulder of the Orion Crew Survival System suits that NASA astronauts Reid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results